| CAS | 91224-37-2 |
| Sequence | H-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 |
| Sequence Single | rPKPQQwFwLL-NH2 |
| Molecular Formula | C75H108N20O13 |
| Molecular Weight | 1497.81 |
| Synonyms | (D-Arg1,D-Trp7.9,Leu11)-Substance P, [DArg1, DTrp7,9, Leu11] Substance P |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Description | Spantide I also called (D-Arg1,D-Trp7.9,Leu11)-Substance P, [DArg1, DTrp7,9, Leu11] Substance P, is a high potency substance P antagonist with a weak spasmogenic and a poor histamine releasing effect. Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation. |
| References | 1. A synthetic peptide that is a bombesin receptor antagonist. R.T.Jensen et al., Nature, 309, 61 (1984) 2. Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect. R.Hakanson et al., Regul. Pept., 31, 75 (1990) 3. Biological evaluation of substance P antagonists. K.Folkers et al., Br. J. Pharmacol., 83, 449 (1984) 4. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. J C Beaujouan, et al. Br J Pharmacol. 1993 Mar;108(3):793-800. 5. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. M Zubrzycka, et al. Endocr Regul. 2000 Mar;34(1):13-8. 6. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Linda D Hazlett, et al. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):797-807. |